Global Psoriatic Arthritis (PsA) Market– Industry Tren ds and Forecast to 2029

Análisis y tamaño del mercado

La artritis psoriásica es un tipo de artritis que afecta a algunas personas que tienen psoriasis, una enfermedad de la piel caracterizada por zonas rojas y escamas plateadas. La mayoría de los pacientes padecen psoriasis primero y luego artritis psoriásica; sin embargo, los problemas articulares pueden comenzar antes de que aparezcan las manchas en la piel. Los principales indicios y síntomas de la artritis psoriásica incluyen dolor, rigidez y edema en las articulaciones. La artritis psoriásica puede afectar cualquier región del cuerpo, incluidas las yemas de los dedos y la columna vertebral, y los síntomas pueden variar de moderados a graves. La artritis psoriásica puede afectar a uno o ambos lados de las articulaciones del cuerpo.

Data Bridge Market Research analiza que el mercado de la artritis psoriásica (PsA) se valoró en USD 11,26 mil millones en 2021 y se espera que alcance los USD 23,10 mil millones para 2029, registrando una CAGR del 9,40% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Definición de mercado

La artritis psoriásica (APs) es una enfermedad inflamatoria que afecta las articulaciones y las zonas donde los tendones y ligamentos se unen a los huesos. La artritis psoriásica no tiene cura. Los principales objetivos del tratamiento son controlar la inflamación en las articulaciones afectadas para evitar el dolor y el deterioro de las articulaciones y controlar la afectación de la piel. Los fármacos de venta con receta, conocidos como fármacos antirreumáticos modificadores de la enfermedad (FARME), son uno de los tratamientos más comunes. En el caso de las personas con artritis psoriásica leve, los fármacos antiinflamatorios no esteroides (AINE) pueden ayudar a aliviar el dolor y la inflamación. Se pueden utilizar articulaciones artificiales de metal y plástico para reemplazar algunas de las articulaciones que han sido destruidas significativamente por la artritis psoriásica.

Dinámica del mercado de la artritis psoriásica (APs)

Conductores

• Aumento de la prevalencia de la artritis psoriásica (APs)

La creciente prevalencia de la artritis psoriásica (APs) es un factor importante que impulsa la tasa de crecimiento del mercado de la artritis psoriásica (APs). La artritis psoriásica es una enfermedad degenerativa relacionada con la psoriasis. La afección puede causar daños irreparables en las articulaciones si no se trata de manera adecuada y oportuna. Aunque se desconoce la causa específica de la enfermedad, las investigaciones revelan que los factores genéticos son responsables de aproximadamente el 40 % de los casos. 

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de la artritis psoriásica (PsA) es el creciente gasto en atención médica que ayuda a mejorar su infraestructura.

Además, las crecientes iniciativas de organizaciones públicas y privadas para difundir la información sobre la artritis psoriásica (APs) ampliarán el mercado. Además, los altos ingresos disponibles y el cambio en el estilo de vida de las personas darán lugar a la expansión del mercado de la artritis psoriásica (APs). Junto con esto, el aumento de la población geriátrica y el aumento de la aprobación de terapias biológicas mejorarán la tasa de crecimiento del mercado.

Oportunidades

• Aumento del número de actividades de investigación y desarrollo       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the psoriatic arthritis (PsA) market growth. The launch of breakthrough medicines in the psoriatic arthritis treatment market is driving research-driven understanding of the pathophysiology of psoriatic arthritis, stimulating innovations among market participants – thereby promoting the growth of the psoriatic arthritis treatment market. Targeted biological therapy has a good success rate in producing transient pain alleviation in patients with psoriatic arthritis, and hence continues to hold a promising position in the psoriatic arthritis treatment market.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of psoriatic arthritis (PsA) during the forecast period.

Restraints/Challenges

On the other hand, high cost of the medication will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and low awareness about psoriatic arthritis (PsA) and its associated complications will pose major challenges to the market's growth rate. Additionally, the dearth of favorable reimbursement policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This psoriatic arthritis (PsA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the psoriatic arthritis (PsA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The psoriatic arthritis (PsA) market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

• In December 2021, AbbVie announced the U.S. Food and Drug Administration (FDA) approval of RINVOQ (upadacitinib; 15 mg, once daily) for treating adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. RINVOQ is a JAK inhibitor that is being researched for use in various immune-mediated inflammatory disorders. RINVOQ showed stronger inhibitory potency for JAK-1 compared to JAK-2, JAK-3, and TYK-2 in enzymatic and cellular studies.

Global Psoriatic Arthritis (PsA) Market Scope

The psoriatic arthritis (PsA) market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Symmetric PsA
• Asymmetric PsA
• Spondylitis PsA
• Psoriatic Arthritis Mutilans
• Distal Interphalangeal Predominant PsA

Treatment

• Medication
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Disease-modifying antirheumatic drugs (DMARDs)
• Immunosuppressant
• Corticosteroids
• Others
• Surgery
• Joint replacement surgery
• Others
• Others

Diagnosis

• X-rays
• Magnetic Resonance Imaging (MRI)
• Others

Route of Administration

• Oral
• Topical
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Psoriatic Arthritis (PsA) Market Regional Analysis/Insights

The psoriatic arthritis (PsA) market is analysed and market size insights and trends are provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the psoriatic arthritis (PsA) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the psoriatic arthritis (PsA) market because of the growing presence of major key players and the rising number of research and development activities will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to the surging number of generic manufacturers and growing government initiatives in this region. Also, the development of healthcare infrastructure will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Psoriatic Arthritis (PsA) Market Share Analysis

The psoriatic arthritis (PsA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to psoriatic arthritis (PsA) market.

Some of the major players operating in the psoriatic arthritis (PsA) market are:

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Cadila Pharmaceuticals (India) 
• Eli Lilly and Company (U.S.)
• LEO Pharma A/S (Denmark)
• Cipla Inc. (U.S.)
• Aurobindo Pharma (India)
• Lupin (India)
• Sumitomo Corporation (Japan)

SKU-53467